? CANCER GENETICS AND GENOMICS PROGRAM The Duke Cancer Institute?s Cancer Genetics and Genomics (CGG) Program is a basic science program whose goals are to define the genetic changes that drive tumorigenesis, to understand the origins and consequences of these changes, and to use the knowledge gained to inform cancer diagnosis and treatment. CGG members use diverse and complementary experimental approaches that include structural biology, biochemistry, cell biology, genetics and genomics and employ model organisms as well as pre-clinical models. Within the Duke Cancer Institute (DCI), the CGG Program serves as the primary source of genetics and genomics expertise and broadly facilitates the application of ?omics? technologies to assess alterations in cancer genomes, epigenomes and transcriptomes. As such, the Program coordinates DCI research activities related to the study and understanding of cancer genetics, epigenetics, gene expression, genome instability and genomics. The CGG fosters interactions and collaborations with other DCI programs. The CGG Program is organized into three focus groups: (1) Genomics and Epigenetics, (2) Recombination, Replication and Repair, and (3) Viral Oncology and Microbiomes. These focus groups reflect the diversity of factors that promote the development of cancer and alter the course of the disease. Each focus group provides opportunities for interaction and collaboration through research-in progress meetings and mini-symposia. In addition, each focus group is closely aligned with a T32 training grant that facilitates the education/mentoring goals of the Program and the DCI. The CGG fosters interactions between the focus groups through a monthly program-wide seminar and quarterly meetings designed to foster collaboration and multi-PI grants. The CGG program is comprised of 35 primary members and 25 secondary members from 10 departments and two schools within Duke University. Total direct funding for primary program members is $10.3M, of which $8.8M is peer reviewed, including $2.5M from the NCI. From 2014-2018, program members published 451 papers in peer-reviewed journals, 12% were intra-programmatic and 31% inter-programmatic collaborations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955
Powell Gray, Bethany; Kelly, Linsley; Ahrens, Douglas P et al. (2018) Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A 115:4761-4766
Abdi, Khadar; Lai, Chun-Hsiang; Paez-Gonzalez, Patricia et al. (2018) Uncovering inherent cellular plasticity of multiciliated ependyma leading to ventricular wall transformation and hydrocephalus. Nat Commun 9:1655
Hudson, Kathryn E; Rizzieri, David; Thomas, Samantha M et al. (2018) Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. Br J Haematol :
Fayanju, Oluwadamilola M; Park, Ko Un; Lucci, Anthony (2018) Molecular Genomic Testing for Breast Cancer: Utility for Surgeons. Ann Surg Oncol 25:512-519
Porter, Laura S; Fish, Laura; Steinhauser, Karen (2018) Themes Addressed by Couples With Advanced Cancer During a Communication Skills Training Intervention. J Pain Symptom Manage 56:252-258

Showing the most recent 10 out of 513 publications